Market Radar
資本市場雷達
把最新文章重新整理成投資人最常追蹤的市場訊號:BD、估值、臨床催化、CMC、GLP-1、腫瘤精準治療、AI 製藥與製藥巨頭策略。
腫瘤精準治療
9 篇Merck's TroFuse-015 met its overall-survival endpoint in previously treated gastroesophageal adenocarcinoma. The progression-free survival endpoint was not met.
默沙東向科倫博泰取得大中華區以外的開發與商業化權利。這次胃食道腺癌全球三期達到總生存期主要終點,無惡化存活期未達標。原始協議和後續年報揭露了簽約款及已收到的臨床里程碑款。
On October 19, 2026, the U.S. FDA granted accelerated approval to GSK's Jemperli (dostarlimab), based on AZUR-1 data, for adults with stage II/III locally advanced rectal cancer with deficient mismatch repair or high microsatellite instability (dMMR/MSI-H). Patients receive immunotherapy first. Those who achieve a clinical complete response may, after evaluation, be managed nonoperatively under close surveillance, potentially avoiding surgery and radiation while preserving the rectum. [1]
2026 年 10 月 19 日,美國 FDA 加速核准 GSK 的 Jemperli(dostarlimab),依據 AZUR-1 資料,用於成人第 II/III 期錯配修復缺陷/微衛星高度不穩定(dMMR/MSI-H)的局部晚期直腸癌。病人先接受免疫治療,若達到臨床完全反應,經評估後可在密切追蹤下採取非手術管理,有機會不開刀、不放療,保住直腸。[1]
諾華證實 Zolgensma 上市以來收到九例腫瘤通報,兩例找到載體嵌入致癌基因 GLI1,FDA 被報導已展開調查並延伸到 Itvisma。嬰兒版會留下並加追蹤;被重算的是諾華靠 Itvisma 打開的大童與成人市場。
BeOne said on November 5 that its BTK degrader tacabrutideg met a pivotal Phase 2 goal, with a filing planned for mid-2027, while Veppanu, the first approved PROTAC, earned Arvinas only $0.5 million in Q3 2026 royalties. Astellas has a KRAS G12D degrader in Phase 3, and Taiwan's AnHorn is pursuing a topical AR degrader for hair loss.
GLP-1 與代謝賽道
7 篇Ribupatide中國三期48週平均減重17.7%,安慰劑1.4%。四試驗的週數與人群不同;三計畫60.35億美元名目上限中,已付首款與技轉費1.10億美元。
The Last Mile After Weight Loss
減肥之後的最後一哩路
On Nov 9 FDA required NAION warnings on all GLP-1 labels, including Mounjaro and the Foundayo pill. Taiwan had labeled only semaglutide and began a class review on Nov 10. We unpack the 1.7x ratio, the lawsuits and Taiwan's next step.
FDA 11 月 9 日要求所有 GLP-1 仿單加註罕見視神經病變 NAION,連猛健樂與口服 Foundayo 都在內;台灣只先處理 semaglutide,食藥署 11 月 10 日啟動再評估。我們拆解 1.7 倍風險的分母、官司與台灣仿單的下一步。
AASLD 2026 data show GLP-1s resolve MASH far more than they reverse fibrosis. Novo's Akero CVR and Roche's 89bio CVR both hinge on cirrhosis, while Rezdiffra grew 50% with up to 53% GLP-1 co-use.
臨床與法規催化
9 篇兩項全球一線NSCLC研究以OS終點地位作比較;交易金額與台灣關聯不代表可比療效或核准領先。
On November 15, 2026, Summit announced an FDA complete response letter for ivonescimab. The HARMONi primary OS analysis yielded p=0.057, missing the prespecified 0.0448 threshold.
Summit於2026年11月15日公告收到ivonescimab完整回覆函;HARMONi主要OS分析p值0.057,未達0.0448的門檻。
FDA approved Bayer's Sunharbo on Nov 9, two weeks after China. It cut ischemic stroke 26% without a significant rise in major bleeding and lists at $748.50 a month. BMS and J&J report milvexian stroke data by end-2026.
FDA 11 月 9 日核准拜耳 Sunharbo,首個 Factor XIa 抑制劑;中國 10 月 26 日先批。三期試驗再中風降 26%、大出血無顯著增加,美國月價 748.5 美元。必治妥與嬌生的 milvexian 中風數據年底前公布。
Novartis confirmed nine tumor reports after Zolgensma, two with vector DNA near the GLI1 oncogene; the FDA reportedly extends the risk to Itvisma. Infant use stays; the older-patient market gets repriced.
BD / 授權與併購
5 篇The OBI–Novartis ADC agreement separates a $30m upfront from conditional milestones, with exclusivity defined by selected payload classes and key funding and retained-rights terms undisclosed.
浩鼎與諾華的平台合作約定3,000萬美元簽約金,總潛在價值逾20億美元;拆解酬載排他範圍、條件款、研究分工與未揭露條款。
Boehringer Ingelheim paid SBP Group $358M upfront for six preclinical ADC and T-cell engager programs (up to ~$7.36B). Taiwan's nine 2026 out-licensing deals disclosed one upfront, $10M. The gap has two layers: what Taiwan sells, and how much human data it has.
百靈佳殷格翰 11 月 4 日向中國生物製藥買下 6 個臨床前 ADC 與 T 細胞接合器,帳面最高約 73.6 億美元、首付 3.58 億美元;台灣 2026 年 9 筆對外授權公開總額約 8.3 億美元,唯一公開首付 1,000 萬美元。差距有兩層:台灣賣的多是改良型新藥、生物相似藥與單一國家權利;就算是新一代平台,韓國首付仍只有中國同類案的約九分之一,買方付錢買的是臨床數據規模。
TAHO (6467) closed at NT$246 on Nov 3, 2026, up 133% from its NT$105.6 IPO price on Japanese royalty news. A BMS-Pfizer patent suit in Delaware can stay final FDA approval of BEQIA for up to 30 months, Medicare's negotiated Eliquis price already fell 56% in 2026, and settled generics enter from April 1, 2028: BEQIA's US value depends on when, and at what price, it can launch.